35092-83-2

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 1-amino-2-naphthoate is used as a precursor in the synthesis of various pharmaceuticals for its potential role in the treatment of different diseases and disorders. Its unique chemical properties and potential biological activities make it a promising candidate for drug development.
Used in Organic Chemistry Research:
In the field of organic chemistry, Methyl 1-amino-2-naphthoate is utilized as a valuable building block for the development of new chemical processes and compounds. Its structure and reactivity are instrumental in creating innovative organic molecules and reactions.

Upstream product

• 67-56-1 methanol 
• 103588-91-6 1,2-dihydronaphth<1,2-d><3,1>oxazin-2,4(1H)-dione 
• 4919-43-1 1-amino-2-naphthoic acid 
• 103987-83-3 1-nitro-2-naphthoic acid 
• 176853-40-0 2-<β-trans-(N,N-dimethylamino)ethenyl>-1-nitronaphthalene 
• 881-03-8 1-nitro-2-methylnaphthalene 
• 78508-71-1 methyl 1-nitro-2-naphthoate 

Downstream Products

• 1227924-42-6 1-amino-4-bromo-2-naphthoic acid 
• 1227924-20-0 3-((1S,2S)-2-hydroxycyclohexyl)-6-((6-(methylthio)pyridin-3-yl)methyl)benzo[h]quinazolin-4(3H)-one 
• 1227924-28-8 3-((1S,2S)-2-hydroxycyclohexyl)-6-((6-methoxypyridin-3-yl)methyl)benzo[h]quinazolin-4(3H)-one 
• 1227923-29-6 3-[(1S,2S)-2-hydroxycyclohexyl]-6-[(6-methylpyridin-3-yl)methyl]benzo[h]quinazolin-4(3H)-one 
• 1227923-94-5 6-((6-chloropyridin-3-yl)methyl)-3-((1S,2S)-2-hydroxycyclohexyl)benzo[h]quinazolin-4(3H)-one 
• 1227924-49-3 3-((1S,2S)-2-hydroxycyclohexyl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)benzo[h]quinazolin-4(3H)-one 
• 1227924-44-8 6-bromo-3-[(1S,2S)-2-hydroxycyclohexyl]benzo[h]quinazolin-4(3H)-one 
• 1227924-43-7 1-amino-4-bromo-N-[(1S,2S)-2-hydroxycyclohexyl]-2-naphthamide 

Relevant academic research and scientific papers

Benzo[f]benzo[5,6]indolo[3,2-b]indole: A stable unsubstituted 4nπ-electron acene with an antiaromatic 1,4-diazapentalene core

A stable unsubstituted 4nπ-electron acene with an antiaromatic 1,4-diazapentalene core was prepared via an unprecedented mild oxidation. Further investigation showed that the stability of such acenes was dependent on the fusion patterns of the peripheryl benzene rings to the centre core. The Royal Society of Chemistry 2014.

MK-7622: A First-in-Class M1 Positive Allosteric Modulator Development Candidate

Identification of ligands that selectively activate the M1 muscarinic signaling pathway has been sought for decades to treat a range of neurological and cognitive disorders. Herein, we describe the optimization efforts focused on addressing key physicochemical and safety properties, ultimately leading to the clinical candidate MK-7622, a highly selective positive allosteric modulator of the M1 muscarinic receptor that has entered Phase II studies in patients with Alzheimer's disease.

M1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR COMPOUNDS AND METHODS OF USE THEREOF

The present invention is directed to compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein Q, X, Y, Z, R1, R7 and n are defined herein. The compounds of Formula (I) are M1 receptor positive allosteric modul

DIHYDROBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to dihydrobenzoquinazilinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease

AMINOBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to aminobenzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimers disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor

PYRANYL ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to pyranyl aryl methyl benzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as ALzheimer?s disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor

ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to benzoquinazilinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.